Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

NCT02485899 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT02485899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02485899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2015
Completion date
December 10, 2020
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

batten disease, cln2 disease, cln2 disorder, jansky-bielschowsky disease, late-infantile neuronal ceroid lipofuscinosis type 2